Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market.
Read the article on CNBC >
Read More from the Global Wellness News ™